撤回：MEK1/2 抑制剂 AZD6244 增敏 BRAF 突变型甲状腺癌对威罗非尼的敏感性。
Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
机构信息
Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
Department of Thyroid Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
出版信息
Med Sci Monit. 2022 Mar 7;28:e936571. doi: 10.12659/MSM.936571.
This publication has been retracted by the Editor due to the identification of falsified figure images and manuscript content that raise concerns regarding the credibility of the study and the manuscript. Reference: Vemurafenib Hao Song, Jinna Zhang, Liang Ning, Honglai Zhang, Dong Chen, Xuelong Jiao, Kejun Zhang. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. Med Sci Monit, 2018; 24: 3002-3010. DOI: 10.12659/MSM.910084.
本文已被编辑撤回，原因是发现伪造的图像和手稿内容，这引起了人们对该研究和手稿可信度的关注。参考文献：vemurafenib Hao Song，Jinna Zhang，Liang Ning，Honglai Zhang，Dong Chen，Xuelong Jiao，Kejun Zhang。MEK1/2 抑制剂 AZD6244 增敏 BRAF 突变型甲状腺癌对 vemurafenib 的敏感性。医学科学监测，2018；24：3002-3010。DOI：10.12659/MSM.910084。
Zotero 插件